Katharine A. Kirby

Katharine A. Kirby

Auto-generated profile, based on publicly available information

Katharine A. Kirby

B Department of Pharmacology, School of Medical Sciences , University of Sydney , Sydney , NSW , Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2008 in JAMA
Verified
Journal Article
Open access
PDF file
ALAjit Limaye
Ajit Limaye
KKKatharine A. Kirby
Katharine A. Kirby
GRGordon D. Rubenfeld
Gordon D. Rubenfeld
WLWendy M. Leisenring
Wendy M. Leisenring
EBEileen M. Bulger
Eileen M. Bulger
MBMichael Boeckh
Michael Boeckh
Cytomegalovirus (CMV) has long been recognized as an important viral pathogen in immunocompromised hosts. In addition to direct effects of CMV due to viral replication and resultant tissue injury, a range of indirect effects have been attributed to CMV in immunocompromised patients, including increased risk of secondary bacterial and fungal infections,1-5 predisposition to specific malignancies such as Epstein-Barr virus–associated posttransplant lymphoproliferative disorder,6 cardiovascular disease,7,8 and mortality.2-5,9,10 A causal role of CMV in mediating these indirect effects is supported by studies of antiviral prophylaxis in immunosuppressed patients demonstrating reductions in secondary bacterial and fungal infections,2-5 hospitalization,11 and mortality.2-5

15 February 2007 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
AUA. Upton
A. Upton
KKK. A. Kirby
K. A. Kirby
PCP. Carpenter
P. Carpenter
MBM. Boeckh
M. Boeckh
KMK. A. Marr
K. A. Marr
Invasive aspergillosis (IA) is a leading cause of infection-related mortality following hematopoietic cell transplantation (HCT). The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time. Cases of proven and probable IA diagnosed in HCT recipients at the Fred Hutchinson Cancer Research Center from 1 January 1990 through 31 December 2004 were included. Patient data were collected from a prospectively maintained database and by retrospective clinical chart review. Survival was estimated using Kaplan-Meier curves, and Cox regression models were used for multivariable analyses. Four hundred five cases were identified. The probability of survival at 90 days after diagnosis was higher for patients identified as having IA between 2002 and 2004 than for patients whose IA was diagnosed in preceding years (45% vs. 22%; P<.001). Risk factors independently associated with all-cause mortality include impairment in pulmonary function before HCT, receipt of human leukocyte antigen-mismatched stem cells, neutropenia, elevated bilirubin and creatinine levels, receipt of corticosteroids at > or =2 mg/kg per day, disseminated and proven IA, and IA occurring >40 days after HCT. Factors associated with a decreased risk of all-cause mortality included receipt of nonmyeloablative conditioning and peripheral blood stem cells. In a subanalysis of attributable mortality restricted to patients receiving antifungal therapy, receipt of voriconazole was independently associated with protection from IA-related death. There has been a significant decrease in mortality in patients with a diagnosis of IA following HCT in recent years, coinciding with multiple changes in transplantation practices, including use of nonmyeloablative conditioning regimens, receipt of peripheral blood stem cells, more prompt diagnosis of IA, and use of voriconazole.

15 October 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal
AUArlo Upton
Arlo Upton
KKKatharine A. Kirby
Katharine A. Kirby
KMKieren A. Marr
Kieren A. Marr
Background. Invasive mold infections (IMIs) are common in individuals who have undergone hematopoietic stem cell transplantation (HSCT). We sought to

22 July 2014 in Neurology
Verified
Journal Article
Closed access
PDF file
DBDeborah E. Barnes
Deborah E. Barnes
AKAllison Kaup
Allison Kaup
KKKatharine A. Kirby
Katharine A. Kirby
ABAmy L. Byers
Amy L. Byers
RDRamon Diaz-Arrastia
Ramon Diaz-Arrastia
KYKristine Yaffe
Kristine Yaffe
Objectives: Traumatic brain injury (TBI) is common in military personnel, and there is growing concern about the long-term effects of TBI on the brain; however, few studies have examined the association between TBI and risk of dementia in veterans. Methods: We performed a retrospective cohort study of 188,764 US veterans aged 55 years or older who had at least one inpatient or outpatient visit during both the baseline (2000–2003) and follow-up (2003–2012) periods and did not have a dementia diagnosis at baseline. TBI and dementia diagnoses were determined using ICD-9 codes in electronic medical records. Fine-Gray proportional hazards models were used to determine whether TBI was associated with greater risk of incident dementia, accounting for the competing risk of death and adjusting for demographics, medical comorbidities, and psychiatric disorders. Results: Veterans were a mean age of 68 years at baseline. During the 9-year follow-up period, 16% of those with TBI developed dementia compared with 10% of those without TBI (adjusted hazard ratio, 1.57; 95% confidence interval: 1.35–1.83). There was evidence of an additive association between TBI and other conditions on risk of dementia. Conclusions: TBI in older veterans was associated with a 60% increase in the risk of developing dementia over 9 years after accounting for competing risks and potential confounders. Our results suggest that TBI in older veterans may predispose toward development of symptomatic dementia and raise concern about the potential long-term consequences of TBI in younger veterans and civilians.

1 December 2006 in Infection and Immunity
Verified
Journal Article
Closed access
JBJin Woo Bok
Jin Woo Bok
DCDaWoon Chung
DaWoon Chung
SBS. Arunmozhi Balajee
S. Arunmozhi Balajee
KMKieren A. Marr
Kieren A. Marr
DADavid Andes
David Andes
Nancy KellerNancy Keller
Nancy Keller
Gliotoxin is a nonribosomal peptide produced byAspergillus fumigatus. This compound has been proposed as anA. fumigatusvirulence factor due to its cytotoxic, genotoxic, and apoptotic properties. Recent identification of the gliotoxin gene cluster identified several genes (gligenes) likely involved in gliotoxin production, includinggliZ, encoding a putative Zn2Cys6binuclear transcription factor. Replacement ofgliZwith a marker gene (ΔgliZ) resulted in no detectable gliotoxin production and loss of gene expression of otherglicluster genes. Placement of multiple copies ofgliZin the genome increased gliotoxin production. Using endpoint survival data, theΔgliZand a multiple-copygliZstrain were not statistically different from the wild type in a murine pulmonary model; however, both the wild-type and the multiple-copygliZstrain were more virulent thanΔlaeA(a mutant reduced in production of gliotoxin and other toxins). A flow-cytometric analysis of polymorphonuclear leukocytes (PMNs) exposed to supernatants from wild-type,ΔgliZ, complementedΔgliZ, andΔlaeAstrains supported a role for gliotoxin in apoptotic but not necrotic PMN cell death. This may indicate that several secondary metabolites are involved inA. fumigatusvirulence.

9 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NNNinh T. Nguyen
Ninh T. Nguyen
JCJustine Chinn
Justine Chinn
MFMorgan De Ferrante
Morgan De Ferrante
KKKatharine A. Kirby
Katharine A. Kirby
SHSamuel F. Hohmann
Samuel F. Hohmann
AAAlpesh Amin
Alpesh Amin
Introduction: The coronavirus disease 2019 (COVID-19) pandemic continues to be a global threat, with tremendous resources invested into identifying risk factors for severe COVID-19 illness. The objective of this study was to analyze the characteristics and outcomes of male compared to female adults with COVID-19 who required hospitalization within US academic centers. Methods: Using the Vizient clinical database, discharge records of adults with a diagnosis of COVID-19 between March 1, 2020 and November 30, 2020 were reviewed. Outcome measures included demographics, characteristics, length of hospital stay, rate of respiratory intubation and mechanical ventilation, and rate of in-hospital mortality of male vs female according to age, race/ethnicity, and presence of preexisting comorbidities. Results: Among adults with COVID-19, 161,206 were male while 146,804 were female. Adult males with COVID-19 were more likely to have hypertension (62.1% vs 59.6%, p <0.001%), diabetes (39.2% vs 36.0%, p <0.001%), renal failure (22.3% vs 18.1%, p <0.001%), congestive heart failure (15.3% vs 14.6%, p <0.001%), and liver disease (5.9% vs 4.5%, p <0.001%). Adult females with COVID-19 were more likely to be obese (32.3% vs 25.7%, p<0.001) and have chronic pulmonary disease (23.7% vs 18.1%, p <0.001). Gender was significantly different among races (p<0.001), and there was a lower proportion of males versus females in African American patients with COVID-19. Comparison in outcomes of male vs. female adults with COVID-19 is depicted in Table 2. Compared to females, males with COVID-19 had a higher rate of in-hospital mortality (13.8% vs 10.2%, respectively, p <0.001); a higher rate of respiratory intubation (21.4% vs 14.6%, p <0.001); and a longer length of hospital stay (9.5 ± 12.5 days vs. 7.8 ± 9.8 days, p<0.001). In-hospital mortality analyzed according to age groups, race/ethnicity, payers, and presence of preexisting comorbidities consistently showed higher death rate among males compared to females (Table 2). Adult males with COVID-19 were associated with higher odds of mortality compared to their female counterparts across all age groups, with the effect being most pronounced in the 18–30 age group (OR, 3.02 [95% CI, 2.41–3.78]). Conclusion: This large analysis of 308,010 COVID-19 adults hospitalized at US academic centers showed that males have a higher rate of respiratory intubation and longer length of hospital stay compared to females and have a higher death rate even when compared across age groups, race/ethnicity, payers, and comorbidity.